Canaccord Genuity Maintains Buy on DexCom, Lowers Price Target to $82

Benzinga Newsdesk www.benzinga.com Neutral 52.1%

Neg 0% Neu 52.1% Pos 0%

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $100 to $82.